uniQure N.V.
- QURE
- NASDAQ
- Biotechnology
- Gene Therapy
- Rare Disease Treatments
- Hemophilia Gene Therapy
$21.83
Today +0.23%Quote Oct 19, 2026, 02:04 PM UTC
−50.60%over the last month
Max drawdown −53.7%From 1-month high −51.9%3 months −45.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.51B
Quote Oct 19
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$52.18
+139.0% from here
Floor
$21.49
1.6% below price
Where the price sits
38 analysts
Analyst range, low to high
$28.00$80.00
- Price $21.83
- Resistance $22.54
- Consensus $52.18
The price is just above its floor. Analysts' average target sits about 139% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about QUREPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q4 2025 revenue $5.6M
- License revenues$5.5M99.2%
- Collaboration revenues$45,0000.8%
Industry
Biotechnology
Employees
221
Founded
1998